C-Suite

Caleres announced Kathleen Welter has joined the company as chief human resources officer. Welter will oversee all human resources functions for the company’s portfolio of brands and its more than 9,000 Associates worldwide, including recruitment, talent management, training, culture, compensation, benefits and labor law compliance. Welter will be a member of the company’s leadership team and will report to President and CEO Jay Schmidt. She will be based in St. Louis.

Doug Koch, current chief human resources officer, will remain at Caleres for a 30-day transition period with Welter and to support special projects until his retirement at year-end.

Welter brings nearly three decades of human resources experience to Caleres with expertise in aligning talent with strategic vision and organizational objectives. Most recently she was the principal lead for the HR team at Woodard & Curran as vice president of human resources, where she oversaw senior executive recruitment and succession planning, restructured performance, development and compensation strategies, and led HR integration of acquisitions. Previously, Welter was a senior consultant at Talent Equation where she grew the company’s consulting practice by partnering with a diverse base of clients to support organizational design and team development. She is returning to Caleres where she worked for a decade, first as director of talent management and then as vice president of talent strategy and leadership continuity. Welter has her MBA and bachelor’s degree from the University of Missouri.

GoodRx, the leading platform for medication savings in the U.S., today announced the appointment of Laura Jensen as Chief Commercial Officer and President of Pharma Solutions, effective July 28, 2025. In this role, Laura will lead the company’s Pharma Manufacturer Solutions offering and oversee strategic initiatives aimed at growing and enhancing innovative partnerships across the pharmaceutical industry. Her deep cross-sector experience uniquely positions her to help revolutionize how patients access and afford their medications through the GoodRx platform.

Laura joins GoodRx from Amazon Pharmacy, where she served as Head of Manufacturer & Prescriber Business Development. There, she led strategic partnerships that reimagined how patients access and manage their medications across both Amazon Pharmacy and PillPack. Her team was responsible for developing integrated experiences that connect prescribers and pharmacy workflows, driving innovation in patient engagement and health outcomes.

“We are thrilled to have Laura join our executive team,” said Wendy Barnes, President and Chief Executive Officer of GoodRx. “We believe her deep experience across pharmaceutical, consumer health, and pharmacy ecosystems—combined with her passion for improving patient access—makes her uniquely suited to lead our growing Pharma Manufacturer Solutions business. We are confident that Laura will help us deepen our impact and accelerate growth, ultimately helping the industry reimagine how patients access the care they need.”

Prior to her time at Amazon Pharmacy and PillPack, Laura held influential roles at several leading pharmaceutical companies, including UCB and GlaxoSmithKline, where she led initiatives focused on sales, marketing, operations, and commercial innovation. Her cross-functional industry expertise and holistic view of the healthcare ecosystem will help ensure GoodRx continues pioneering new ways to advance patient access and affordability.

“Now, more than ever, pharma companies recognize that patients are looking for new ways to access their medications in the changing ecosystem of healthcare,” said Jensen. “I’m thrilled to join the GoodRx team that has built the most trusted and widely used medication savings platform by consumers and healthcare professionals in the country. By combining GoodRx’s large reach and scale with innovative access solutions, we have an incredible opportunity to help more people start and stay on the treatments they need.”

Jazz Pharmaceuticals announced that the Jazz Board of Directors has unanimously selected Renee Gala, Jazz’s President and Chief Operating Officer, as the President and Chief Executive Officer, effective August 11, 2025, when she will also join the Board. She will succeed co-founder, Chairperson and CEO Bruce Cozadd, who informed the Board in December 2024 of his intent to retire as CEO upon the identification of the Company’s next leader. This appointment reflects a key milestone in the Board’s long-term succession planning process and previously disclosed CEO transition.

Ms. Gala was promoted to the role of President and COO in October 2023, after having served as Executive Vice President and Chief Financial Officer of the Company since March 2020. She brings more than 30 years of experience across finance, strategy, corporate development and commercialization. In her current role, she oversees the Company’s global business operations, which include commercial, medical, research and development, technical operations and quality, as well as corporate strategy. Ms. Gala has played a critical role in driving Jazz’s ongoing transformation, including architecting a business development strategy that has diversified the Company’s portfolio, driven total revenue growth of nearly 90%, built broad capabilities, and established a pipeline that has positioned the Company for value creation and sustainable growth.

“The Board conducted a thorough and thoughtful search including both internal and external candidates, and we’re highly confident that Renee is exactly the right leader to build on Jazz’s momentum,” said Rick Winningham, Lead Independent Director. “The Board’s priority was to find an exceptional leader who could not only operate the business but also serve as a catalyst in driving long-term growth at this important moment for the Company. Among a field of highly capable and qualified candidates, Renee was the clear standout, with a compelling set of experiences and skillsets, as well as a strong track record of driving high performance and change at Jazz through both corporate development and operational initiatives. The Board has a strong focus on Jazz’s evolution and delivering value, and we believe Renee is ideally equipped to drive and deliver Jazz’s continued success.”

“I am honored to step into the CEO role and build upon Jazz’s extraordinary legacy, fueled by exceptional people, a spirit of purpose and an unwavering commitment to patients,” said Ms. Gala. “With a market-leading portfolio of medicines, a promising pipeline, a strong financial position and an ongoing focus on corporate development, Jazz has immense potential—and more work to be done to realize it. I look forward to continuing the important efforts underway and working with our team to pursue new opportunities—both within our portfolio and through external innovation—to drive greater value for our patients and shareholders. I want to express my deep appreciation to Bruce for his steadfast leadership over the past two decades in building an organization defined by patient-centricity and mutual respect, a foundation that will serve us well into the future. I’m grateful for the opportunity to have partnered with Bruce over the last five years and look forward to continuing to work with him and the Board in this next chapter.”

“I co-founded Jazz 22 years ago and am immensely proud of our journey. From the beginning, our mission has been to work tirelessly to transform patient lives,” said Mr. Cozadd. “We have since grown into an innovative biopharma company with expanded commercial and scientific capabilities to drive the next phase of our evolution, and a value rich pipeline poised to reach even more patients than we ever thought possible. I am thrilled to be handing over the reins to Renee and am excited for her to lead Jazz into our next phase of growth. In her role as Jazz’s CFO and then as our President and COO, Renee’s leadership has been critical in Jazz’s transformation into a high-growth biopharmaceutical company fueled by a strong R&D pipeline and robust commercial operations. I am confident that she will continue to further this mission as CEO, while nurturing the culture that makes Jazz such a compelling place to spend your career.”

Mr. Cozadd will continue to serve as Chairperson of the Board, providing strategic input as the Company continues to execute on its growth strategy.

Peloton Interactive, Inc. has appointed Megan Imbres to its leadership team as Chief Marketing Officer.

Megan Imbres, who will join the company on July 7, will oversee global brand and product marketing, growth marketing, creative, consumer insights, and member engagement. She brings more than 20 years of experience with direct-to-consumer brands, including expertise in data-driven performance marketing, brand development, and creative strategy for some of the world’s most influential technology and entertainment companies. She will report to CEO Peter Stern.

Megan most recently served as Managing Director of Apple Marcom LA, the global marketing communications group responsible for the company’s services businesses, overseeing significant creative campaigns and delivering tentpole cultural moments, including the Apple Music Super Bowl Halftime Show and Apple TV’s partnership with Major League Soccer. Prior to Apple, Megan played a pivotal role in the growth of Netflix, first helping to build the brand and streaming category before later establishing the Netflix Originals brand. Other previous positions include Global Head of Brand Marketing for Amazon Ads and Head of Brand and Content Marketing for the mobile streaming startup Quibi, working closely with founders Jeffrey Katzenberg and Meg Whitman. She is also a passionate cyclist and competitive triathlete, recently qualifying for the Kona Ironman 2025 World Championships.

“Megan’s experience in growing direct-to-consumer subscription businesses, her creative instincts, and her track record of delivering culturally resonant campaigns will propel us on our path towards growth,” said Stern. “I look forward to working alongside her and our fantastic marketing organization as we deepen our connection with our millions of existing Members and meet millions of new ones.”

Brinker International, Inc. announced the promotion of longtime Brinker leader Aaron White to Executive Vice President, Chief Operating Officer and Chief People Officer for the company’s restaurant brands, Chili’s® Grill & Bar and Maggiano’s Little Italy®.

In this expanded role, she will oversee both Operations strategy and PeopleWorks across the Restaurant Support Center, Chili’s and Maggiano’s, with her leadership team focused on driving the company’s next level of operational improvements to improve the team member and guest experience.

White began her Brinker career 29 years ago as a Chili’s server and bartender and has most recently served as Executive Vice President and Chief People Officer. Aaron has a track record of significant results in her almost three decades in Operations and PeopleWorks roles. Prior to her role as Brinker CPO, she was Chili’s Co-Chief Operating Officer, supporting the brand’s eastern U.S. locations. Aaron’s teams have delivered huge results in the company’s turnaround through simplification, redesigning work processes to be more efficient, and reawakening the ChiliHead culture that has been a key to Chili’s success for the brand’s 50 years.

“Aaron has earned deep respect across the organization for her ability to strategize, get things done, bring people together, and elevate our culture. She’s the kind of leader who both delivers results and does it in the right way that is both sustainable and culture-building,” said Brinker CEO and President Kevin Hochman. “As we look toward our future growth and continue our simplification journey in our restaurants, Aaron will lead her team with deep expertise to ensure our operators’ jobs are easier, more fun, and more rewarding and the Guest experience remains top of mind.”

In April 2025, she was named to the Nation’s Restaurant News Power List: Women in Foodservice for her significant role in shaping the company’s culture and driving organizational change.

White will continue reporting to Brinker CEO and President Kevin Hochman.